Arm CEO: AI Cancer Cures Slowed by Chip Shortage — SkimNews
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Rene Haas, Arm Holdings CEO, told the BBC AI will help cure cancer in our lifetimes, calling current DNA-cancer modelling "too complex" for humans and today's computers but solvable as models and computing power grow.
- Arm Holdings is in a "supply-constrained environment" with chip shortages delaying AI data centre rollouts; Haas said "we need more fabs" before multi-gigawatt data centres planned for France, the US, and space can be built.
- UK chip manufacturing won't happen anytime soon, according to Haas, who called fabs "very expensive" with heavy demands for specialised workers and natural resources, despite government talks about bringing the supply chain home.
- Meta commissioned Arm's Arm AGI chip, generating over $2bn in demand since its March launch, while Arm's power-efficient technology now powers half of AI data centres worldwide.
- Humanoid robots powered by Arm chips will be widespread in five to ten years, Haas predicted, reprogrammable for tasks from making beds and arranging towels to building bridges and repairs.
- AI-driven job losses fears are "a bit overstated," Haas said, and stock market correction worries over AI companies are similarly overstated given long-term demand.
- Prof Chris Bakal of the Institute of Cancer Research pushed back, saying the future of medical AI "will not belong to whoever builds the biggest computer" but to whoever has the right measurements from patient samples.
Why it matters: The chip bottleneck is now a concrete ceiling on AI's most ambitious projects — from cancer modelling to multi-gigawatt and even space-based data centres. Arm's $2bn AGI chip demand marks a strategic shift from pure IP licensor to chip seller, while Haas's dismissal of UK fabs leaves Britain's AI ambitions tethered to overseas production dominated by Taiwan's TSMC.
Ask SkimNews
